Neurophet has signed a supply agreement with the Tokyo Metropolitan Institute for Geriatrics and Gerontology for its brain imaging software Neurophet AQUA, the company said Tuesday.

AQUA rapidly quantifies brain atrophy and white matter changes from MRI and provides disease-specific reports for Alzheimer’s disease and vascular dementia.

Neurophet said the deal will help secure a meaningful reference in Japan. Co-CEO Jake Been said it provides a “foothold” for future expansion. The institute specializes in geriatric medicine; Vice President Atsushi Iwata, M.D., Ph.D., recently joined Neurophet as a scientific adviser. 

Neurophet added that its AI programs include AQUA for MRI, SCALE PET for PET imaging, and AQUA AD for Alzheimer’s disease analysis. All three are registered with the Japan Radiological Society and certified for additional reimbursement under the national health insurance system.